(Q40392402)

20 September 2017

1 reference

title

Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy (English)

1 reference

20 September 2017

1 reference

1

R N Brogden

1 reference

20 September 2017

A Fitton

2

1 reference

20 September 2017

1 June 1994

1 reference

20 September 2017

1 reference

20 September 2017

47

1 reference

20 September 2017

6

1 reference

20 September 2017

983-1009

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199447060-00008

20 September 2017

0 references

cites work

Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics

1 reference

12 December 2020

Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy

1 reference

12 December 2020

The activity of rifabutin against Mycobacterium leprae

1 reference

12 December 2020

Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa.

1 reference

12 December 2020

Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters

1 reference

12 December 2020

In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs

1 reference

12 December 2020

Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network

1 reference

12 December 2020

Rifampin and ansamycin interactions with cyclosporine after renal transplantation

1 reference

12 December 2020

Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on mycobacterium intracellulare

1 reference

12 December 2020

[Rifabutine in the treatment of mycobacterial infections resistant to rifampicin. Preliminary results. Group for the Study and Treatment of Resistant Mycobacterial Infections (GETIM)]

1 reference

12 December 2020

Bioavailability of rifampicin capsules.

1 reference

12 December 2020

Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome.

1 reference

12 December 2020

Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice

1 reference

12 December 2020

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

12 December 2020

Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex

1 reference

12 December 2020

Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis

1 reference

12 December 2020

Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man.

1 reference

12 December 2020

The emergence of drug-resistant tuberculosis in New York City

1 reference

12 December 2020

Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections

1 reference

12 December 2020

Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi

1 reference

12 December 2020

Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex

1 reference

12 December 2020

Diarrhoea associated with Clostridium difficile in AIDS patients receiving rifabutin

1 reference

12 December 2020

Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents

1 reference

12 December 2020

Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid

1 reference

12 December 2020

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

12 December 2020

The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare

1 reference

12 December 2020

Rifabutin-induced ageusia

1 reference

12 December 2020

In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin

1 reference

12 December 2020

Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774.

1 reference

12 December 2020

Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine

1 reference

12 December 2020

Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects

1 reference

12 December 2020

Recurrent Bacterial Infections in Children

1 reference

12 December 2020

Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

1 reference

12 December 2020

Pharmacokinetics of rifabutin

1 reference

12 December 2020

Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis

1 reference

12 December 2020

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

12 December 2020

Rifabutin absorption in humans: relative bioavailability and food effect

1 reference

12 December 2020

In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method

1 reference

12 December 2020

Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects

1 reference

12 December 2020

Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals

1 reference

12 December 2020

In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae

1 reference

12 December 2020

Rifabutin treatment for tuberculosis patients with liver function abnormalities

1 reference

12 December 2020

Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex

1 reference

12 December 2020

Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium

1 reference

12 December 2020

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

1 reference

12 December 2020

Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice

1 reference

12 December 2020

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

1 reference

12 December 2020

Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients

1 reference

12 December 2020

Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations

1 reference

12 December 2020

In vitro efficacy of several antibiotics against intracellular S. aureus in chronic granulomatous disease

1 reference

12 December 2020

Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs

1 reference

12 December 2020

Activity of azithromycin against Mycobacterium avium infection in beige mice

1 reference

12 December 2020

A study of the effects of rifabutin on isoniazid pharmacokinetics and metabolism in healthy volunteers

1 reference

12 December 2020

Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers

1 reference

12 December 2020

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

1 reference

12 December 2020

LM 427,a new spiropiperidylrifamycin: In vitro and in vivo studies

1 reference

12 December 2020

Clinical Pharmacokinetics of Rifampicin

1 reference

12 December 2020

Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum

1 reference

12 December 2020

Bactericidal activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis

1 reference

12 December 2020

[In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex]

1 reference

12 December 2020

Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.

1 reference

12 December 2020

In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice

1 reference

12 December 2020

In vivo activities of newer rifamycin analogs against Mycobacterium avium infection

1 reference

12 December 2020

Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare

1 reference

12 December 2020

Rifabutin and rifapentine compared with rifampin against Mycobacterium leprae in mice

1 reference

12 December 2020

Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients

1 reference

12 December 2020

In VitroActivity of Clarithromycin Alone or in Combination with Other Antimicrobial Agents againstMycobacterium avium-intracellulare.Complex Strains Isolated from AIDS Patients

1 reference

12 December 2020

Rifabutine minimum inhibitory concentrations (MICs) for non-tuberculous mycobacteria in liquid medium by a radiometric method

1 reference

12 December 2020

Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth

1 reference

12 December 2020

Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution

1 reference

12 December 2020

Natural History of Disseminated Mycobacterium avium Complex Infection in AIDS

1 reference

12 December 2020

Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS.

1 reference

12 December 2020

Differences in antimicrobial susceptibility of pigmented and unpigmented colonial variants of Mycobacterium avium

1 reference

12 December 2020

Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare

1 reference

12 December 2020

Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria

1 reference

12 December 2020

In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin

1 reference

12 December 2020

Antibiotics and host defence with special reference to phagocytosis by human polymorphonuclear leukocytes

1 reference

12 December 2020

Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex

1 reference

12 December 2020

In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae

1 reference

12 December 2020

Autoinduction of rifabutin metabolism in man.

1 reference

12 December 2020

Intraphagocytic penetration of antibiotics

1 reference

12 December 2020

Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods

1 reference

12 December 2020

Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes

1 reference

12 December 2020

Intracellular parasites and phagocytic cells: cell biology and pathophysiology.

1 reference

12 December 2020

Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages

1 reference

12 December 2020

Mycobacterioses and the acquired immunodeficiency syndrome. Joint Position Paper of the American Thoracic Society and the Centers for Disease Control

1 reference

12 December 2020

Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS

1 reference

12 December 2020

Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome

1 reference

12 December 2020

Effect of rifabutin on the phagocytosis and intracellular growth of Mycobacterium intracellulare in mouse resident and activated peritoneal and alveolar macrophages

1 reference

12 December 2020

Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex

1 reference

12 December 2020

Activity of clarithromycin against Mycobacterium avium complex infection in beige mice

1 reference

12 December 2020

Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome

1 reference

12 December 2020

Pharmacokinetic drug interactions with rifampicin

1 reference

12 December 2020

Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis

1 reference

12 December 2020

Antibiotics and Phagocytosis

1 reference

12 December 2020

Determination of in vitro susceptibility of mycobacteria to ansamycin

1 reference

12 December 2020

Activity of antimicrobial agents against Mycobacterium avium-intracellulare complex (MAC) strains isolated in Italy from AIDS-patients

1 reference

12 December 2020

10.2165/00003495-199447060-00008

Identifiers

DOI

1 reference

PubMed ID

7521834

Dimensions Publication ID

20 September 2017

0 references

1 reference

PubMed ID

7521834